

Correction

Correction: Phenformin enhances the therapeutic effect of selumetinib in KRAS-mutant non-small cell lung cancer irrespective of LKB1 status

Jun Zhang^{1,2,3}, Sreenivas Nannapaneni², Dongsheng Wang², Fakeng Liu², Xu Wang², Rui Jin², Xiuju Liu², Mohammad Aminur Rahman², Xianghong Peng², Guoqing Qian², Zhuo G. Chen², Kwok-Kin Wong⁴, Fadlo R. Khuri^{1,2}, Wei Zhou^{1,2} and Dong M. Shin^{1,2}

¹Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA 30322, USA

²Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA 30322, USA

³Division of Hematology, Oncology and Blood & Marrow Transplantation, Department of Internal Medicine, Holden Comprehensive Cancer Center, University of Iowa Carver College of Medicine, Iowa City, IA 52242, USA

⁴Dana-Farber Cancer Institute, Harvard Medical School, Dana Building 810B, HIM243, Boston, MA 02115, USA

Published:

Copyright: © 2021 Zhang et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](#) (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

This article has been corrected: Due to an error in our inventory system, the pBabe-LKB1-mutant plasmid purchase from Addgene was mislabeled as K78M instead of K78I. Therefore, all the cell lines containing mutant LKB1 should be labeled K78I, not K78M, throughout this article. The authors declare that these corrections do not change the results or conclusions of this paper.

Original article: Oncotarget. 2017; 8:59008–59022. <https://doi.org/10.18632/oncotarget.19779>